<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941105</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT-SIRIO 5</org_study_id>
    <nct_id>NCT04941105</nct_id>
  </id_info>
  <brief_title>Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19</brief_title>
  <acronym>IMPACT-SIRIO 5</acronym>
  <official_title>Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19: the Randomized, Double-blind, Phase III IMPACT-SIRIO 5 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPACT-SIRIO 5 is a randomized, double-blind, phase III clinical trial aimed to evaluate&#xD;
      safety and efficacy of PCSK9 inhibition on clinical outcome in patients during the&#xD;
      inflammatory stage of the COVID-19. During the hospitalization participants will be&#xD;
      randomized in a 1:1 ratio to either receive PCSK9 inhibitor (evolocumab) or to receive&#xD;
      placebo (saline solution). Furthermore, all people included in the study will be treated in&#xD;
      accordance to the latest recommendations on the treatment of patients infected with&#xD;
      SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for intubation</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>The indications for intubation determined individually for each patient and clinical status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>Death from any cause during hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum interleukin-6 concentration from day 0 to day 3</measure>
    <time_frame>3 days from randomization</time_frame>
    <description>Primary laboratory endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum interleukin-6 concentration from day 0 to day 7</measure>
    <time_frame>7 days from randomization</time_frame>
    <description>Primary laboratory endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time of invasive mechanical ventilation</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>Defined as the number of days between intubation and extubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time with Non-invasive mechanical ventilation (NIV) or High-flow nasal cannula (HFNC)</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>Defined as the number of days between initiation and cessation of Non-invasive mechanical ventilation (NIV) or High-flow nasal cannula (HFNC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time with oxygen therapy</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>Defined as the number of days of oxygen therapy (including all methods of oxygen therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of hospitalization</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
    <description>Defined as the number of days that pass between the day of hospital admission and discharge or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of oxygen therapy before discharge</measure>
    <time_frame>during hospitalization, up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sars-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>PCSK9 inhibitor (evolocumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>A single subcutaneous administration of 140 mg evolocumab</description>
    <arm_group_label>PCSK9 inhibitor (evolocumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>A single subcutaneous injection of 1ml of 0,9% saline solution</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent for participation in the study&#xD;
&#xD;
          2. Male and female age 18 or more at the time of signing the informed consent&#xD;
&#xD;
          3. SARS-CoV-2 infection confirmed by Real-Time Reverse Transcription Polymerase Chain&#xD;
             Reaction (RT-PCR)&#xD;
&#xD;
          4. COVID-19 pneumonia with a typical radiological changes&#xD;
&#xD;
          5. PaO2/FIO2 ratio less than or equal to 300&#xD;
&#xD;
          6. COVID-19 Pneumonia in cytokine storm with elevated serum level of interleukin-6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of fibrates other than fenofibrate or fenofibric acid&#xD;
&#xD;
          2. Known active infections or other clinical condition that contraindicate PCSK9&#xD;
             inhibitors&#xD;
&#xD;
          3. Known systemic hypersensitivity to PCSK9 inhibitors&#xD;
&#xD;
          4. Estimated glomerular filtration rate &lt;30 ml/min/1.73 m2&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) less than 2000/mm3&#xD;
&#xD;
          6. A platelet count less than 50000/mm3&#xD;
&#xD;
          7. Creatine kinase (CK) greater than 3x upper limit of normal (ULN)&#xD;
&#xD;
          8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3x&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
          9. Not expected to survive for more than 48 hours from screening&#xD;
&#xD;
         10. Unrelated co-morbidity with life expectancy &lt;3 months.&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. Any physical examination findings and/or history of any illness that, in the opinion&#xD;
             of the study investigator, might confound the results of the study or pose an&#xD;
             additional risk to the patient by their participation in the study&#xD;
&#xD;
         13. Patient being treated with other immunomodulators (except for glucocorticoids).&#xD;
&#xD;
         14. Patient included in any other interventional trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Przemysław Podhajski</last_name>
    <phone>+48 52 585 4023</phone>
    <email>przemyslaw.podhajski@cm.umk.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antoni Jurasz University Hospital No. 1</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Podhajski</last_name>
      <phone>+48 585 4023</phone>
      <email>przemyslaw.podhajski@cm.umk.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Head of Department of Cardiology and Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 Pneumonia</keyword>
  <keyword>PCSK9 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

